Role of Anti-Hepatitis C Virus (HCV) Treatment in HCV-Related, Low-Grade, B-Cell, Non-Hodgkin's Lymphoma: A Multicenter Italian Experience

Abstract

This experience strongly provides a role for antiviral treatment in patients affected by HCV-related, low-grade, B-cell NHL.

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

“…Antiviral treatment (AT) has been shown to induce remission of MC-related clinical manifestations and to reduce their transformation to overt B-NHL [12]. In patients with low-grade HCV-related NHL, clearance of HCV infection can lead to regression of the tumour burden [13][14][15]. Moreover, there is a correlation between hematological and virologic responses in patients with MZL, constituting the strongest indicator linking HCV infection with lymphomagenesis [13].…”

Clinical and biological diversity of splenic marginal zone lymphoma

“…The low incidence of SMZL among the low grade B-cell lymphomas and leukemias has made it difficult to gather information on its pathogenesis. Although the etiology of SMZL is unknown, it has been suggested that, in some patients, a chronic persistent antigen stimulation by the hepatitis C virus [6][7][8], the malaria parasite [9], or even by an autoantigen or a hitherto unknown foreign antigen, is responsible for initiating and triggering the disease. This first step would initiate a polyclonal expansion of B cells in the marginal zone of the spleen, followed by second hits resulting in the deregulation of genes involved in lymphomagenesis, leading to the emergence of an independent clonal lymphoid proliferation and ending with For reprint orders, please contact reprints@expert-reviews.com the lymphoma.…”

Characterization of B cell lymphoma in patients with Sjögren's syndrome and hepatitis C virus infection

“…Unfortunately, no data are available for the therapeutic management of lymphoma in patients with SS-HCV. In B cell lymphomas, diverse therapeutic options have been used, including conventional chemotherapy (31), monoclonal agents (41), antiviral (42) or antimicrobial agents (43), and, in some cases, no specific therapy (23). This heterogeneity in treating B cell lymphoma was also observed in our retrospective multicenter series of patients with SS-HCV, although etiopathogenically, 2 therapeutic options should be highlighted as future options.…”